By licensing a drug from Hansoh, Merck signaled that it isn’t prepared to fully challenge its rivals’ dominance in the GLP-1 space.
Our daily email brings you smart and engaging news and analysis on the biggest stories in business and finance. For free.
Modifi Biosciences announced that it has been acquired by global pharmaceutical giant Merck, with a $30 million down payment.
Neuralink wants to protect implants from interference.
Moderna says it was willing to licence the tech but now wants to be repaid by rivals for vaccine revenue generated since then.
Bioprospecting for genes of new species in the world’s oceans has become complex and extremely lucrative.
The company’s stock ran higher after the company buoyed investors’ hopes that its technology will boost a lineup of new popular drugs.
The growing sector scored its second-highest month ever for total money-raising.
Some of pharma’s biggest players — including Merck, Amgen, Abbvie, and Gilead — formed an alliance to fight looming M&A reforms.
There were plenty of business losers in 2024, but only one for whom the sky was literally falling. In short: Boeing had a bad year.
Luxury brands were riding the subway instead of lounging in limos this year, though a couple of brands were able to buck the trend.
As the dealmaking environment improved in 2024 thanks to the bull market and interest-rate cuts, investment bankers reaped a windfall.